ReviewBMC ophthalmology2023
Research progress on the pathogenesis of diabetic retinopathy.
Review in BMC ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating microRNAs as biomarkers for diabetic retinopathy stage identification: A DTA systematic review and meta-analysis.PloS one · 2025Pooled it
- MicroRNAs: A Social Network in Diabetic Retinopathy.Biomolecules · 2026Review
- Review
- Integrative transcriptomic and machine learning analysis identifies key extracellular matrix-related genes in diabetic retinopathy.Scientific reports · 2026Article
- Knocking Down CDKN2A Enhances the Therapeutic Effects of Metformin and Resveratrol on Diabetic Retinopathy.Applied biochemistry and biotechnology · 2026Article
- FTO-modulated mJournal of translational medicine · 2026Article
- The Effects of GLP-1 Receptor Agonists on Retinal Microvascular Alterations.Biomedicines · 2026Review
- Causal Links of Type 2 Diabetes and Its Complications With Cortical Modification: A Mendelian Randomization and Mediation Analysis.Brain and behavior · 2026Article
- miR-103a-3p contributes to diabetic retinopathy progression via suppressing MFN2.Diabetology & metabolic syndrome · 2026Article
- Catestatin and Diabetic Retinopathy in Type 2 Diabetes Mellitus.Biomedicines · 2026Article
- Serum and urinary mindin as a potential biomarker for diabetic retinopathy: a prospective cross-sectional study.BMC ophthalmology · 2026Article
- The ANGPTL3-integrin α5 axis drives retinal vascular leakage in diabetic retinopathy.Journal of translational medicine · 2026Article
- Relationship between hemoglobin levels and diabetic retinopathy in Chinese type 2 diabetes mellitus populations: a cross-sectional study.Frontiers in endocrinology · 2026Article
- Vacuolar protein sorting 35 regulates retinal neurovascular functionInternational journal of ophthalmology · 2026Article
- Crosstalk between gut microbiota and RNA N6-methyladenosine modification in diabetic retinopathy.Frontiers in cell and developmental biology · 2026Review
- Association of Serum Vitamin D With Macular Microvascular Structure in Type 2 Diabetic Mellitus Without Diabetic Retinopathy: A Cross-Sectional Study.Journal of diabetes research · 2026Observational
- Artificial intelligence-driven diabetic retinopathy research: mapping the evolution, coupling, and global collaboration landscape (1996-2026).Frontiers in endocrinology · 2026Review
- Development and Novel Therapeutics in Diabetic Retinopathy.Current diabetes reviews · 2026Review
- Targeting the NEK7/NLRP3 Inflammasome Axis: Synergistic Protection of Intravitreal MCC950 and Systemic Metformin Against Diabetic Retinopathy in Rats.Endocrinology, diabetes & metabolism · 2026Article
- Factors associated with diabetic retinopathy among patients with diabetes in rural Guangxi, China: a multicenter cross-sectional study.Frontiers in endocrinology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Diabetic retinopathy is one of the most common and serious microvascular complications of diabetes mellitus. There are many factors leading to diabetic retinopathy, and its pathogenesis is still unclear. At present, there are still no effective measures for the early treatment of diabetic retinopathy, and the treatment options available when diabetes progresses to advanced stages are very limited, and the treatment results are often unsatisfactory. Detailed studies on the molecular mechanisms of diabetic retinopathy pathogenesis and the development of new therapeutic agents are of great importance. This review describes the potential pathogenesis of diabetic retinopathy for experimental studies and clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.